Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia
Objective To compare the clinical effect of arsenic-containing Qinghuang Powder (QHP) and low-intensity chemotherapy (LIC) in treatment of elderly acute myeloid leukemia (eAML) patients. Methods Clinical data of 80 eAML patients treated at Xiyuan Hospital of China Academy of Chinese Medical Sciences...
Gespeichert in:
| Veröffentlicht in: | Chinese journal of integrative medicine 2023-09, Vol.29 (9), p.832-837 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 837 |
|---|---|
| container_issue | 9 |
| container_start_page | 832 |
| container_title | Chinese journal of integrative medicine |
| container_volume | 29 |
| creator | Wu, Yu-he Xiao, Hai-yan Quan, Ri-cheng Tang, Xu-dong Liu, Wei-yi Lyu, Yan Chen, Zhuo Liu, Chi Hu, Xiao-mei |
| description | Objective
To compare the clinical effect of arsenic-containing Qinghuang Powder (QHP) and low-intensity chemotherapy (LIC) in treatment of elderly acute myeloid leukemia (eAML) patients.
Methods
Clinical data of 80 eAML patients treated at Xiyuan Hospital of China Academy of Chinese Medical Sciences from January 2015 to December 2020 were retrospectively analyzed. The treatment scheme was designed by real world study according to patients’ preference, and patients were divided into a QHP group (35 cases) and a LIC group (45 cases). The median overall survival (mOS), 1-, 2-, and 3-year OS rates, and incidence of adverse events were compared between the two groups.
Results
The mOS of 80 patients was 11 months, and the 1-, 2-, and 3-year OS rates were 45.51%, 17.96%, and 11.05%, respectively. The QHP and LIC groups demonstrated no significant difference in mOS (12 months
vs.
10 months), 1- (48.57%
vs.
39.65%), 2- (11.43% vs. 20.04%), and 3-year OS rates (5.71% vs. 13.27%, all
P
>0.05). Moreover, the related factors of mOS demonstrated no significant difference in patients with age>75 years (11 months vs. 8 months), secondary AML (11 months vs. 8 months), poor genetic prognosis (9 months vs. 7 months), Eastern Cooperative Oncology Group performance status score ⩾ 3 (10 months vs. 7 months) and hematopoietic stem cell transplant comorbidity index ⩾ 4 (11 months vs. 7 months) between the QHP and LIC groups (all
P
>0.05). However, the incidence of myelosuppression was significantly lower in the QHP group than that in the LIC group (28.57% vs. 73.33%,
P |
| doi_str_mv | 10.1007/s11655-023-3603-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2818745825</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2818745825</sourcerecordid><originalsourceid>FETCH-LOGICAL-c296t-b7bd16e0536b485dbfaf150eeac6513711612182162d6b29c46e781103df380c3</originalsourceid><addsrcrecordid>eNp9kMFu1DAQhi1ERUvhAbggH7kYPPbayR5XUWkrLaKV4Gw5yYR1SexgO1pF4uHxagtHLjO_rG9-yR8h74B_BM6rTwlAK8W4kExqLpl-Qa5gu5WMb7h4WbKuRMmgLsnrlJ44V5Xm6hW5lJUQopZwRX43YZptdP4H3cWE3nWsCT5b509Pj2UcFlvSQzj2GKn1Pd2HI7v3GX1yeaXNAaeQDxjtvFLn6c1YuHGlDzY79DnRo8sHuuuWjPTLimNwpQGXnzg5-4ZcDHZM-PZ5X5Pvn2--NXds__X2vtntWSe2OrO2anvQyJXU7aZWfTvYARRHtJ1WIKtiAQTUArTodSu23UZjVQNw2Q-y5p28Jh_OvXMMvxZM2UwudTiO1mNYkhE11NVG1UIVFM5oF0NKEQczRzfZuBrg5iTdnKWbIt2cpBtdbt4_1y_thP2_i7-WCyDOQJpPpjGap7BEX778n9Y_bvaNjg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2818745825</pqid></control><display><type>article</type><title>Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia</title><source>Alma/SFX Local Collection</source><source>SpringerLink Journals - AutoHoldings</source><creator>Wu, Yu-he ; Xiao, Hai-yan ; Quan, Ri-cheng ; Tang, Xu-dong ; Liu, Wei-yi ; Lyu, Yan ; Chen, Zhuo ; Liu, Chi ; Hu, Xiao-mei</creator><creatorcontrib>Wu, Yu-he ; Xiao, Hai-yan ; Quan, Ri-cheng ; Tang, Xu-dong ; Liu, Wei-yi ; Lyu, Yan ; Chen, Zhuo ; Liu, Chi ; Hu, Xiao-mei</creatorcontrib><description>Objective
To compare the clinical effect of arsenic-containing Qinghuang Powder (QHP) and low-intensity chemotherapy (LIC) in treatment of elderly acute myeloid leukemia (eAML) patients.
Methods
Clinical data of 80 eAML patients treated at Xiyuan Hospital of China Academy of Chinese Medical Sciences from January 2015 to December 2020 were retrospectively analyzed. The treatment scheme was designed by real world study according to patients’ preference, and patients were divided into a QHP group (35 cases) and a LIC group (45 cases). The median overall survival (mOS), 1-, 2-, and 3-year OS rates, and incidence of adverse events were compared between the two groups.
Results
The mOS of 80 patients was 11 months, and the 1-, 2-, and 3-year OS rates were 45.51%, 17.96%, and 11.05%, respectively. The QHP and LIC groups demonstrated no significant difference in mOS (12 months
vs.
10 months), 1- (48.57%
vs.
39.65%), 2- (11.43% vs. 20.04%), and 3-year OS rates (5.71% vs. 13.27%, all
P
>0.05). Moreover, the related factors of mOS demonstrated no significant difference in patients with age>75 years (11 months vs. 8 months), secondary AML (11 months vs. 8 months), poor genetic prognosis (9 months vs. 7 months), Eastern Cooperative Oncology Group performance status score ⩾ 3 (10 months vs. 7 months) and hematopoietic stem cell transplant comorbidity index ⩾ 4 (11 months vs. 7 months) between the QHP and LIC groups (all
P
>0.05). However, the incidence of myelosuppression was significantly lower in the QHP group than that in the LIC group (28.57% vs. 73.33%,
P
<0.01).
Conclusions
QHP and LIC had similar survival rates in eAML patients, but QHP had a lower myelosuppression incidence. Hence, QHP can be an alternative for eAML patients who do not tolerate LIC.</description><identifier>ISSN: 1672-0415</identifier><identifier>EISSN: 1993-0402</identifier><identifier>DOI: 10.1007/s11655-023-3603-6</identifier><identifier>PMID: 37222831</identifier><language>eng</language><publisher>Singapore: Springer Nature Singapore</publisher><subject>Clinical Experience ; Medicine ; Medicine & Public Health</subject><ispartof>Chinese journal of integrative medicine, 2023-09, Vol.29 (9), p.832-837</ispartof><rights>The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature 2023</rights><rights>2023. The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c296t-b7bd16e0536b485dbfaf150eeac6513711612182162d6b29c46e781103df380c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11655-023-3603-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11655-023-3603-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37222831$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Yu-he</creatorcontrib><creatorcontrib>Xiao, Hai-yan</creatorcontrib><creatorcontrib>Quan, Ri-cheng</creatorcontrib><creatorcontrib>Tang, Xu-dong</creatorcontrib><creatorcontrib>Liu, Wei-yi</creatorcontrib><creatorcontrib>Lyu, Yan</creatorcontrib><creatorcontrib>Chen, Zhuo</creatorcontrib><creatorcontrib>Liu, Chi</creatorcontrib><creatorcontrib>Hu, Xiao-mei</creatorcontrib><title>Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia</title><title>Chinese journal of integrative medicine</title><addtitle>Chin. J. Integr. Med</addtitle><addtitle>Chin J Integr Med</addtitle><description>Objective
To compare the clinical effect of arsenic-containing Qinghuang Powder (QHP) and low-intensity chemotherapy (LIC) in treatment of elderly acute myeloid leukemia (eAML) patients.
Methods
Clinical data of 80 eAML patients treated at Xiyuan Hospital of China Academy of Chinese Medical Sciences from January 2015 to December 2020 were retrospectively analyzed. The treatment scheme was designed by real world study according to patients’ preference, and patients were divided into a QHP group (35 cases) and a LIC group (45 cases). The median overall survival (mOS), 1-, 2-, and 3-year OS rates, and incidence of adverse events were compared between the two groups.
Results
The mOS of 80 patients was 11 months, and the 1-, 2-, and 3-year OS rates were 45.51%, 17.96%, and 11.05%, respectively. The QHP and LIC groups demonstrated no significant difference in mOS (12 months
vs.
10 months), 1- (48.57%
vs.
39.65%), 2- (11.43% vs. 20.04%), and 3-year OS rates (5.71% vs. 13.27%, all
P
>0.05). Moreover, the related factors of mOS demonstrated no significant difference in patients with age>75 years (11 months vs. 8 months), secondary AML (11 months vs. 8 months), poor genetic prognosis (9 months vs. 7 months), Eastern Cooperative Oncology Group performance status score ⩾ 3 (10 months vs. 7 months) and hematopoietic stem cell transplant comorbidity index ⩾ 4 (11 months vs. 7 months) between the QHP and LIC groups (all
P
>0.05). However, the incidence of myelosuppression was significantly lower in the QHP group than that in the LIC group (28.57% vs. 73.33%,
P
<0.01).
Conclusions
QHP and LIC had similar survival rates in eAML patients, but QHP had a lower myelosuppression incidence. Hence, QHP can be an alternative for eAML patients who do not tolerate LIC.</description><subject>Clinical Experience</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><issn>1672-0415</issn><issn>1993-0402</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kMFu1DAQhi1ERUvhAbggH7kYPPbayR5XUWkrLaKV4Gw5yYR1SexgO1pF4uHxagtHLjO_rG9-yR8h74B_BM6rTwlAK8W4kExqLpl-Qa5gu5WMb7h4WbKuRMmgLsnrlJ44V5Xm6hW5lJUQopZwRX43YZptdP4H3cWE3nWsCT5b509Pj2UcFlvSQzj2GKn1Pd2HI7v3GX1yeaXNAaeQDxjtvFLn6c1YuHGlDzY79DnRo8sHuuuWjPTLimNwpQGXnzg5-4ZcDHZM-PZ5X5Pvn2--NXds__X2vtntWSe2OrO2anvQyJXU7aZWfTvYARRHtJ1WIKtiAQTUArTodSu23UZjVQNw2Q-y5p28Jh_OvXMMvxZM2UwudTiO1mNYkhE11NVG1UIVFM5oF0NKEQczRzfZuBrg5iTdnKWbIt2cpBtdbt4_1y_thP2_i7-WCyDOQJpPpjGap7BEX778n9Y_bvaNjg</recordid><startdate>20230901</startdate><enddate>20230901</enddate><creator>Wu, Yu-he</creator><creator>Xiao, Hai-yan</creator><creator>Quan, Ri-cheng</creator><creator>Tang, Xu-dong</creator><creator>Liu, Wei-yi</creator><creator>Lyu, Yan</creator><creator>Chen, Zhuo</creator><creator>Liu, Chi</creator><creator>Hu, Xiao-mei</creator><general>Springer Nature Singapore</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20230901</creationdate><title>Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia</title><author>Wu, Yu-he ; Xiao, Hai-yan ; Quan, Ri-cheng ; Tang, Xu-dong ; Liu, Wei-yi ; Lyu, Yan ; Chen, Zhuo ; Liu, Chi ; Hu, Xiao-mei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c296t-b7bd16e0536b485dbfaf150eeac6513711612182162d6b29c46e781103df380c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Clinical Experience</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Yu-he</creatorcontrib><creatorcontrib>Xiao, Hai-yan</creatorcontrib><creatorcontrib>Quan, Ri-cheng</creatorcontrib><creatorcontrib>Tang, Xu-dong</creatorcontrib><creatorcontrib>Liu, Wei-yi</creatorcontrib><creatorcontrib>Lyu, Yan</creatorcontrib><creatorcontrib>Chen, Zhuo</creatorcontrib><creatorcontrib>Liu, Chi</creatorcontrib><creatorcontrib>Hu, Xiao-mei</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Chinese journal of integrative medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Yu-he</au><au>Xiao, Hai-yan</au><au>Quan, Ri-cheng</au><au>Tang, Xu-dong</au><au>Liu, Wei-yi</au><au>Lyu, Yan</au><au>Chen, Zhuo</au><au>Liu, Chi</au><au>Hu, Xiao-mei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia</atitle><jtitle>Chinese journal of integrative medicine</jtitle><stitle>Chin. J. Integr. Med</stitle><addtitle>Chin J Integr Med</addtitle><date>2023-09-01</date><risdate>2023</risdate><volume>29</volume><issue>9</issue><spage>832</spage><epage>837</epage><pages>832-837</pages><issn>1672-0415</issn><eissn>1993-0402</eissn><abstract>Objective
To compare the clinical effect of arsenic-containing Qinghuang Powder (QHP) and low-intensity chemotherapy (LIC) in treatment of elderly acute myeloid leukemia (eAML) patients.
Methods
Clinical data of 80 eAML patients treated at Xiyuan Hospital of China Academy of Chinese Medical Sciences from January 2015 to December 2020 were retrospectively analyzed. The treatment scheme was designed by real world study according to patients’ preference, and patients were divided into a QHP group (35 cases) and a LIC group (45 cases). The median overall survival (mOS), 1-, 2-, and 3-year OS rates, and incidence of adverse events were compared between the two groups.
Results
The mOS of 80 patients was 11 months, and the 1-, 2-, and 3-year OS rates were 45.51%, 17.96%, and 11.05%, respectively. The QHP and LIC groups demonstrated no significant difference in mOS (12 months
vs.
10 months), 1- (48.57%
vs.
39.65%), 2- (11.43% vs. 20.04%), and 3-year OS rates (5.71% vs. 13.27%, all
P
>0.05). Moreover, the related factors of mOS demonstrated no significant difference in patients with age>75 years (11 months vs. 8 months), secondary AML (11 months vs. 8 months), poor genetic prognosis (9 months vs. 7 months), Eastern Cooperative Oncology Group performance status score ⩾ 3 (10 months vs. 7 months) and hematopoietic stem cell transplant comorbidity index ⩾ 4 (11 months vs. 7 months) between the QHP and LIC groups (all
P
>0.05). However, the incidence of myelosuppression was significantly lower in the QHP group than that in the LIC group (28.57% vs. 73.33%,
P
<0.01).
Conclusions
QHP and LIC had similar survival rates in eAML patients, but QHP had a lower myelosuppression incidence. Hence, QHP can be an alternative for eAML patients who do not tolerate LIC.</abstract><cop>Singapore</cop><pub>Springer Nature Singapore</pub><pmid>37222831</pmid><doi>10.1007/s11655-023-3603-6</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1672-0415 |
| ispartof | Chinese journal of integrative medicine, 2023-09, Vol.29 (9), p.832-837 |
| issn | 1672-0415 1993-0402 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2818745825 |
| source | Alma/SFX Local Collection; SpringerLink Journals - AutoHoldings |
| subjects | Clinical Experience Medicine Medicine & Public Health |
| title | Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T14%3A01%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparing%20Arsenic-Containing%20Qinghuang%20Powder%20and%20Low-Intensity%20Chemotherapy%20in%20Elderly%20Patients%20with%20Acute%20Myeloid%20Leukemia&rft.jtitle=Chinese%20journal%20of%20integrative%20medicine&rft.au=Wu,%20Yu-he&rft.date=2023-09-01&rft.volume=29&rft.issue=9&rft.spage=832&rft.epage=837&rft.pages=832-837&rft.issn=1672-0415&rft.eissn=1993-0402&rft_id=info:doi/10.1007/s11655-023-3603-6&rft_dat=%3Cproquest_cross%3E2818745825%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2818745825&rft_id=info:pmid/37222831&rfr_iscdi=true |